Immune Modulation of Innate and Adaptive Responses by CARG-2020 Restore Immunosurveillance and Establish Anti-Tumoral Immunological Memory (049)

Current immunotherapies have proven effective in strengthening antitumor immune responses. However, constant opposing signals from tumor cells and the surrounding microenvironment eventually lead to immune escape. We hypothesize that regulating both the innate and adaptive immune system will provide a robust and long-term antitumoral effect by creating an immunological memory against the tumor. To achieve this, we developed CARG-2020, a virus-like vesicle (VLV), delivering three immune modulators (IL-12, IL-17 antagonist, and shRNA-PD-L1). IL-12 is expected to promote T cell expansion. IL-17 antagonist is expected to prevent a tumor-promoting microenvironment. Finally, shRNA-PD-L1 is expected to preclude pro-tumor macrophages and reverse T cell exhaustion.